TrialJournal of Crohn's & colitis2025

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.

Jean-Frederic Colombel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.